Modality
Degrader
MOA
PLK4i
Target
GIP-R
Pathway
Proteasome
Gastric CaWM
Development Pipeline
Preclinical
~Sep 2010
→ ~Dec 2011
Phase 1
~Mar 2012
→ ~Jun 2013
Phase 2
~Sep 2013
→ ~Dec 2014
Phase 3
~Mar 2015
→ ~Jun 2016
NDA/BLA
~Sep 2016
→ ~Dec 2017
Approved
Mar 2018
→ Mar 2031
ApprovedCurrent
NCT05280537
2,669 pts·Gastric Ca
2018-03→2031-03·Not yet recruiting
NCT05230831
467 pts·WM
2023-10→TBD·Terminated
NCT08814064
2,005 pts·Gastric Ca
2020-01→TBD·Not yet recruiting
+1 more trial
6,093 total pts2 indications
CompletedCurrentUpcoming
Catalysts (2)
2028-01-281.8y awayPh3 Readout· WM
2031-03-275.0y awayPh3 Readout· Gastric Ca
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
Approved
Not yet…
Approved
Not yet…
Approved
Complet…
Approved
Termina…
Catalysts
Ph3 Readout
2028-01-28 · 1.8y away
WM
Ph3 Readout
2031-03-27 · 5.0y away
Gastric Ca
CompletedTerminatedNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05280537 | Approved | Gastric Ca | Not yet recr... | 2669 | EDSS |
| NCT05230831 | Approved | WM | Terminated | 467 | PFS |
| NCT08814064 | Approved | Gastric Ca | Not yet recr... | 2005 | LiverFat |
| NCT08006404 | Approved | WM | Completed | 952 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| AZN-5978 | AstraZeneca | Phase 2/3 | GIP-R | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| AMG-2597 | Amgen | Phase 2/3 | CD38 | |
| Elrarapivir | Regeneron | Phase 1 | GIP-R | |
| Riluinavolisib | Moderna | NDA/BLA | KIF18A | |
| Capifutibatinib | Intra-Cellular | Phase 3 | GIP-R | |
| TNG-8610 | Tango Ther | NDA/BLA | GIP-R | |
| Liravorutinib | Biomea Fusion | Phase 1/2 | GPRC5D |